300 related articles for article (PubMed ID: 27446498)
1. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
[TBL] [Abstract][Full Text] [Related]
2. Association between gastrin-releasing peptide receptor expression as assessed with [
Michalski K; Stoykow C; Bronsert P; Juhasz-Böss I; Meyer PT; Ruf J; Erbes T; Asberger J
Nucl Med Biol; 2020; 86-87():37-43. PubMed ID: 32473549
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
[TBL] [Abstract][Full Text] [Related]
5.
Zhang J; Mao F; Niu G; Peng L; Lang L; Li F; Ying H; Wu H; Pan B; Zhu Z; Chen X
Theranostics; 2018; 8(4):1121-1130. PubMed ID: 29464003
[No Abstract] [Full Text] [Related]
6. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
7. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
8. Gastrin-Releasing Peptide Receptor Antagonist [
Michalski K; Kemna L; Asberger J; Grosu AL; Meyer PT; Ruf J; Sprave T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885214
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
10. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
[TBL] [Abstract][Full Text] [Related]
11. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
12. Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonist
Vats K; Sharma R; Kameswaran M; Satpati D; Dash A
J Pharm Biomed Anal; 2019 Jan; 163():39-44. PubMed ID: 30278325
[No Abstract] [Full Text] [Related]
13. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of [
Fassbender TF; Schiller F; Mix M; Maecke HR; Kiefer S; Drendel V; Meyer PT; Jilg CA
Nucl Med Biol; 2019 Mar; 70():32-38. PubMed ID: 30836254
[TBL] [Abstract][Full Text] [Related]
16. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
17. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.
Popp I; Del Pozzo L; Waser B; Reubi JC; Meyer PT; Maecke HR; Gourni E
Nucl Med Biol; 2017 Feb; 45():22-29. PubMed ID: 27865999
[TBL] [Abstract][Full Text] [Related]
18.
Wang L; Zhang Z; Merkens H; Zeisler J; Zhang C; Roxin A; Tan R; Bénard F; Lin KS
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744904
[TBL] [Abstract][Full Text] [Related]
19. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
20. PET Using a GRPR Antagonist
Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X
J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
